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Edited by Jesus AvilaAbstract Previously, we demonstrated the establishment of
synthetic lethality screening in cultured somatic human cells,
or mouse embryo ﬁbroblasts (MEFs), for chemicals or mutant
genes synergistically lethal with a mutated gene of interest.
Here, we show in MEFs that the usage of RNA interference-
based genetic suppressor elements encoding short hairpin RNAs
(shRNAs) enables for genetic synthetic lethality screening at a
frequency much higher than that achieved before with short trun-
cated sense and antisense RNAs. These ﬁndings open up the pos-
sibility of using in mammalian cells genome-wide shRNA
libraries for genetic synthetic lethality screening at the multi-
gene level.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The completion of the comprehensive sequencing of the hu-
man genome [1,2], as well as the ﬁnishing of the draft sequence
of the mouse genome [3] has created an urgent need to develop
additional functional genomic techniques for the elucidation of
gene function.
The genetic synthetic lethality screen in yeast is a very
powerful functional genomic method because it can reveal
not only interactions between gene products with direct
physical contacts, but also interactions along the same or
parallel pathways [4]. Previously, we established chemical
and genetic synthetic lethality screens in cultured human
cells [5,6]. More recently, we applied the chemical synthetic
lethality technology also to mouse embryo ﬁbroblasts
(MEFs) [7]. Here, we sought to expand the genetic synthetic
lethality screening to MEFs. Previously, we established this
screening in human cells, based on the usage of dominant-
negative genetic suppressor elements (GSEs) of either the
expressible short sense or antisense RNA. The frequency
of a bona ﬁde GSE was only 1–2% from among the totalAbbreviations: GMP, guanosine monophosphate; GMPS, GMP syn-
thetase; HPRT1, hypoxanthine-guanine phosphoribosyl transferase 1;
shRNA, short hairpin RNA; MEF, mouse embryo ﬁbroblasts
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of GSEs among the truncated sense and antisense cDNA
constructs was already observed by others [8]. Consequently,
in order to ablate the activity of a single cellular gene
among say 5000 genes expressed in a particular mammalian
cell, one would have to generate and screen at least 250 000–
500 000 mammalian cell clones, a formidable task by all
means. However, the emergence of gene ablation technolo-
gies based upon the RNA interference (RNAi) phenomenon
has opened up new experimental opportunities [9]. In partic-
ular, the generation of vectors directing the synthesis of
short hairpin RNAs (shRNAs) that are processed to small
interfering RNAs (siRNAs) enables for stable persistent sup-
pression of endogenous gene expression [10,11]. The pSU-
PER mammalian expression vector was designed to direct
the synthesis of shRNA transcripts via the DNA polymerase
III promoter that could be processed to siRNAs, such that a
19-nt inverted repeat is separated by a 9-nt loop [12].
Here, we apply pSUPER plasmid vectors in a genetic syn-
thetic lethality screen in MEFs. We identify, at high frequency,
shRNAs capable of eﬃcient suppression of a cellular gene,
which is synthetic lethal with the gene of interest. Thus, we
establish a genetic synthetic lethality screen in mammalian cells
using stable gene suppression via RNAi.2. Materials and methods
2.1. Plasmids construction
The construction of the episomal HPRT1-tpzGFP survival plasmid
and the pIS integrating sphGFP vector with a zeoR dominant select-
able marker has been previously described [5,6]. pRSV-neo plasmid
was constructed by replacing the CMV promoter within pCMV-neo
vector with a RSV promoter from pREP4 vector (Invitrogen). The
pSUPER vector generated in Agamis group was described [12]. To
generate pSUPER-GMP synthetase (pSUPER-GMPS), three pairs of
target sequence oligonucleotides were designed according to ‘‘siRNA
user guide’’ (T. Tuschl, personal communication). Each one contains
a unique 19-nt double stranded human GMPS target sequence, present
as an inverted repeat, separated by a loop of 9-nt spacer, and tran-
scribed from a DNA polymerase-III H1-RNA gene promoter [12].
The three pairs of DNA oligonucleotides have the following sequences:
PSUPER-GMPS1 F:
5 0 gatccccCATTCTCAGGGAGTCTGGGttcaagagaCCCAGACTCC-
CTGAGAATGtttttggaaa 3 0
pSUPER-GMPS1 R:
5 0 agcttttccaaaaaCATTCTCAGGGAGTCTGGGtctcttgaaCCCAGA-
CTCCCTGAGAATGggg 3 0
pSUPER-GMPS2 F:
5 0 gatccccGGAGCTGTTGTCATTCTGGttcaagagaCCAGAATGA-
CAACAGCTCCtttttggaaa 3 0blished by Elsevier B.V. All rights reserved.
Fig. 1. De novo and salvage pathways of purine biosynthesis. Key
enzymes are underlined. Arrows indicate the action of enzymes.
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5 0 agcttttccaaaaaGGAGCTGTTGTCATTCTGGtctcttgaaCCAGAA-
TGACAACAGCTCCggg 3 0
pSUPER-GMPS3 F:
5 0 gatccccCTTGAAACCAGAGGAGGTTttcaagagaAACCTCCTCT-
GGTTTCAAGtttttggaaa 3 0
pSUPER-GMPS3 R:
5 0 agcttttccaaaaaCTTGAAACCAGAGGAGGTTtctcttgaaAACCTC-
CTCTGGTTTCAAGggg 3 0
pSUPER-GMPS1 contains a 19 nucleotide sequence corresponding to
nucleotides 1791–1809 downstream from the transcription start site of
the human GMPS cDNA, pSUPER-GMPS2 contains nucleotides 76–
94, and pSUPER-GMPS3 contains nucleotides 1068–1086. pSUPER-
GMPS1 and -GMPS2 also share 100% homology to the mouse GMPS
gene, while pSUPER-GMPS3 has four mismatches with the corre-
sponding mouse gene.
2.2. Cell culture, transfections and reagents
The HPRT1-deﬁcient 2TGOR cells (a kind gift from H. Ozer,
UMDNJ) are derivatives of the MEFs BALB/c3T3. SKBR3 cell line
is an ERa-negative breast cancer cell line and was purchased from
the ATCC. The 2TGOR and SKBR3 cell lines were maintained in
DMEM, supplemented with 10% fetal calf serum (FCS) and 4 mM
L-glutamine. All transfections were carried out using LipofectAMINE
Plus reagent (Life Technologies). pSUPER vectors were cotransfected
with pRSV-neo at a 10 to 1 molar ratio, and selection in G418 (Calbio-
chem) was carried out at 1200 lg/ml for 2TGOR cells and at 750 lg/ml
for SKBR3 cells. Mycophenolic acid (MPA) was obtained from Eli
Lily (Indianapolis, IN). Synthetic lethality screening experiments per-
formed in the Zeo-5 cells were carried out in the presence of 12.5 lg/
ml guanine.
For cell toxicity experiments, transfections were performed in 6-well
microplates without hygromycin B selection, the cells were passaged to
10 mm plates two days later, and then G418 selection was carried out.
The obtained colonies were ﬁxed with methanol, stained with Giemsa
reagent, and photographed.
Fluorescent scanning of microtiter plates was previously described
[7].
2.3. Quantitative real-time RT-PCR analysis
Total RNA was isolated from a pool of transfectants of each pSU-
PER construct by EZ-RNA isolation kit (Biological Industries, Israel)
and transcribed into cDNA using EZ-ﬁrst strand cDNA synthesis kit
(Biological Industries, Israel). Real-Time PCR was performed with
FastStart DNA master SYBR Green I kit (Roche) at the LightCycler
instrument (Roche), according to the manufacturers instructions. The
DNA primer sequences were designed for murine GMP synthetase as
follows (sense 5 0-GGTTTGCTGGGAAAATCAGC-3 0 and antisense
5 0-CAGGAATCTCATTGCCAGG-3 0) and for murine b-actin as fol-
lows (sense 5 0-CTGAGAGGGAAATCGTGCGT-3 0 and antisense
5 0-TGTTGGCATAGAGGTCTTTACGG-3 0). The cycling conditions
for the GMP synthetase cDNA included preincubation for 15 min at
95 C and 50 cycles comprised of 15 s at 95 C, 10 s at 59 C, 20 s
at 72 C and 5 s at 81 C. For b-actin, the cycle was identical except
for primer annealing performed at 53 C and the ﬁnal step done at
85 C. At the end of each reaction, melting curve analysis was per-
formed. Each assay included a standard curve of four serial dilution
points. All samples were read at least in triplicates, and values were
normalized for baseline expression and for expression of b-actin
mRNA.3. Results and discussion
3.1. The model system, construction of pSUPER-GMPS
vectors, and testing their activity in mammalian cells
As a model system for the establishment of genetic synthetic
lethality screening, the purine biosynthesis pathway was cho-
sen (Fig. 1), as outlined before [5]. Brieﬂy, biosynthesis of
the essential metabolite GMP is achieved by either the de novo
pathway or, when needed, via the salvage pathway catalyzed
by the enzyme HPRT1. In the HPRT1-deﬁcient MEF cell line2TGOR, inhibiting the IMP dehydrogenase enzyme (IMPDH)
or the GMP synthetase enzyme (GMPS), disrupts the de novo
pathway, leading to synthetic lethality. Such selective pressures
impose retention of the otherwise unstable EBV-based epi-
somal survival plasmid expressing the salvage pathways
HPRT1 cDNA, serving as the gene of interest. Because the
mouse, as well as the human, IMPDH enzyme activity is en-
coded by two diﬀerent genes, an attempt was made to inhibit
the single cellular GMPS gene rather than the two IMPDH
genes. Accordingly, three pSUPER-GMPS vectors were de-
signed and cloned as outlined in Section 2. These sequences
were chosen to represent diﬀerent regions of the GMPS tran-
script, and in order to allow versatility of usage in human
and mouse cells, pSUPER-GMPS1 and pSUPER-GMPS2
share 100% homology to the mouse GMPS cDNA. The target
human sequence present in pSUPER-GMPS3 has four mis-
matches with the corresponding mouse sequence.
We then turned to test the functionality of the pSUPER-
GMPS constructs to suppress expression of the endogenous
cellular GMPS gene. We assumed that stable blocking of
GMPS expression in cells would ablate the de novo pathway
of GMP synthesis, leading in HPRT1-deﬁcient cells such as
the mouse 2TGOR, to a synthetic lethal condition. For this
purpose, equal numbers of 2TGOR cells were cotransfected
by pRSV-neo and either the pSUPER empty vector, or each
one of the three human GMPS sequence-containing pSUPER
constructs, while selecting for colonies resistant to the G418
toxic chemical.
In comparison to empty pSUPER vector and pSUPER-
GMPS3, the relative numbers of colonies residing in
pSUPER-GMPS1 or pSUPER-GMPS2 transfected plates
were severely reduced (Fig. 2A). Next, we tested while using
the same approach the potential dominant-negative activity
of these constructs also in human cells. For this purpose, we
used the human breast cancer cell line SKBR3 but in the ab-
sence of the HPRT1 substrate guanine. As shown in Fig. 2B,
the dominant-negative activity of the constructs is qualitatively
similar with the pSUPER-GMPS1 and pSUPER-GMPS2 vec-
tors being the active ones. Interestingly, pSUPER-GMPS3
whose target sequence is presumably identical to the SKBR3
one is totally inactive. Although we have shown that pSU-
PER-GMPS3 is transcriptionally active in human cells (data
Fig. 3. RNA interference-mediated suppression of cellular GMPS
mRNA. RNA was extracted from pools of transfectants and the
mRNA level of GMPS was tested by real-time PCR. All samples were
read at least in triplicates and values were normalized for b-actin
mRNA expression. The data are represented as percent of the empty
vector control value. The statistical signiﬁcance was tested by t test,
resulting in the value of probability of P < 0.01 for pSUPER-GMPS2
and P < 0.05 for pSUPER-GMPS1.
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in its mRNA processing activity, could account for its lack of
activity. Based on our limited experience, about 50% of the
pSUPER constructs actually suppress the expression of the
mRNAs against which they were designed for. Accordingly,
in contrast to the 1–2% frequency of GSEs among truncated
sense and antisense RNAs for human GMPS [6], two of the
three shRNA constructs were found to impose eﬀective RNAi
in human as well as in mouse cells.
3.2. The pSUPER-GMPS mediated RNA interference
suppresses cellular GMPS mRNA levels
We next examined directly whether expression of pSUPER-
GMPS1 and -GMPS2 leads in 2TGOR-derived cells to RNAi
mediated suppression of cellular GMPS mRNA. For this pur-
pose we resorted to the Zeo-5 cell clone, which served as the
model system for chemical synthetic lethality screening in
MEFs [7]. This cell line is derived from the 2TGOR MEF
and harbors on the one hand an integrated sphGFP transcrip-
tion unit, the EBV-based episomal survival plasmid expressing
the tpzGFP, and the human HPRT1 enzyme. The latter can
complement the HPRT1-deﬁciency in the 2TGOR/Zeo-5 cells.
Loss or retention of the episomal survival plasmid can beFig. 2. pSUPER-GMPS conferred cell toxicity in the HPRT1-deﬁcient
2TGOR MEF cell line (A) or in the SKBR3 human breast cancer cell
line (B). Similar number of cells were stably cotransfected with pRSV-
neo and either pSUPER empty or with each one of the three pSUPER-
GMPS constructs. Two weeks after completing the selection for stable
cell clones, the cells were ﬁxed and stained for colonies visualization.determined by measuring the ﬂuorescence intensity ratio be-
tween tpzGFP and sphGFP readings. To generate a putative
synthetic lethal condition, we cotransfected Zeo-5 cells, after
removal of the hygromycin B selection pressure from the
episome, with pRSV-neo and each one of pSUPER-GMPS1,
-GMPS2, or the pSUPER empty vector. Stable clones were
obtained by the selection for G418 resistance. We have then
isolated about 20 clones from each transfection, while the
remaining colonies in each set were pooled for total RNA
extraction.
To compare the relative levels of the corresponding cellular
GMP synthetase mRNA, we performed a quantitative real-
time PCR analysis. In comparison to the endogenous GMP
synthetase mRNA level of pSUPER empty vector-transfec-
tants, the respective mRNA level of pSUPER-GMPS1 pooled
transfectants drops by 60%, whereas in the better expressed
pSUPER-GMPS2 vector (data not shown) Zeo-5 pooled
transfectants there is an 83% decrease in mRNA levels (Fig.
3). As the levels of the cellular GMPS mRNA were normalized
in each case against the murine beta actin mRNA levels, serv-
ing as an internal control (see Section 2), this shRNA mediated
suppressing activity is obviously gene speciﬁc. Taking into ac-
count that total RNA was extracted from pooled MEF trans-
fectants, rather than individual colonies (veriﬁed for
maintenance of the target sequence transcription unit), GMPS
mRNA decay levels may be considered as an underestimation
for the potency of the respective pSUPER-GMPS constructs.
3.3. Expression of GMPS shRNAs confers synthetic lethality
upon Zeo-5 cells
We next examined whether the expression of pSUPER-
GMPS1 and -GMPS2 in Zeo-5 cells leads to retention of the
episomal survival plasmid reﬂecting a synthetic lethal condi-
tion. As outlined above, we have isolated about 20 clones from
transfection with pRSV-neo and each one of pSUPER-
GMPS1, -GMPS2, or the pSUPER empty vector. The individ-
ual colonies were propagated and seeded into microtiter plates.
Two weeks later, the microtiter plates were read for tpzGFP
and sphGFP ﬂuorescence. As shown in Fig. 4, in cells transfec-
ted by either pSUPER-GMPS1 or pSUPER-GMPS2 vector
there is a shift in the ﬂuorescence ratio distribution towards
Fig. 4. Expression of GMPS sequence-containing shRNAs confers
synthetic lethality. Zeo-5 cells were stably cotransfected with pRSV-
neo DNA and either pSUPER-empty vector, pSUPER-GMPS1 or
pSUPER-GMPS2. One month after the transfection, about 20
individual cell clones from each transfection were isolated and grown
in microtiter plates in triplicates without the hygromycin B selection
pressure. The tpzGFP to sphGFP ﬂuorescence ratio was read two
weeks after the cell seeding. Depicted is the fraction of cell clones (Y-
axis) as a function of the GFPs ﬂuorescence ratio (X-axis). The
statistical signiﬁcance was tested by F-test, resulting in the value of
probability of 0.012 for pSUPER-GMPS2 and 0.025 for pSUPER-
GMPS1.
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Zeo-5 cells transfected with pSUPER empty vector. High ﬂuo-
rescent ratio represents the retention of the GFP-tagged epi-
somal survival plasmid. These data indicate that the
previously observed cell death associated with either pSU-
PER-GMPS1 or pSUPER-GMPS2 induced RNAi (Fig. 2) re-
ﬂects in each case the generation of a synthetic lethal condition
(Fig. 4).
We have demonstrated in this work that the stable RNAi
methodology can be incorporated into a genetic synthetic
lethality screening technology. This has been demonstrated
in MEF cells, thus opening up the application of the genetic
synthetic lethality screening to the multitude of knockout mice,
representing deﬁciencies in variety of potential genes of inter-
est. Since the EBV-based episomal survival plasmid is practi-
cally the same in mouse and human cells [5,7], obviously the
same methodology applies also to human cells. Importantly,
several groups have reported recently the generation and usage
of multi-gene human and mouse shRNA-encoding libraries
[13,14]. Such libraries, constructed within retroviral vectors,
can therefore be readily transduced into genetic synthetic
lethality screening in human or MEF cell systems, grown in
96-well microplates, while monitoring periodically the
tpzGFP-tagged episomal plasmid retention. In this respect,
an alternative procedure for genetic synthetic lethality screen-
ing has been recently suggested by the makers of the shRNA
expression libraries [13–15]. This one is based on the DNA
bar-codes strategy enabling identiﬁcation of individual shRNA
construct in complex populations via microarray analysis. Theavailability of such human/mouse shRNA expression libraries
coupled with our ﬁndings opens up the possibility of perform-
ing a relatively straightforward procedure for identiﬁcation of
genes synthetic lethal with a gene of interest; such as target
genes for anticancer therapy linked via synthetic lethality rela-
tionship to mutated tumor suppressor genes.
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